A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes
Status:
Withdrawn
Trial end date:
2024-11-08
Target enrollment:
Participant gender:
Summary
The main aim of the study is to see if signs and symptoms of myelodysplastic syndromes
disappear when treated with pevonedistat combined with decitabine and cedazuridine.
Participants will receive an infusion of pevonedistat 3 times during a 28-day cycle. They
will also take decitabine and cedazuridine tablets once a day for the first 5 days of the
same cycle. A minimum of 6 28-day cycles is recommended, but participants can stop treatment
at any time.
A bone marrow biopsy, bone marrow aspirates, and blood samples will be collected during the
study.
Participants will attend a follow-up visit 30 days after their last dose of pevonedistat.
Once treatment has ended, participants will be followed up with either monthly clinic visits
or will be contacted every 3 months.